Analysts Set Envista Holdings Co. (NYSE:NVST) Price Target at $20.18

Shares of Envista Holdings Co. (NYSE:NVST) have received a consensus recommendation of “Hold” from the fifteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $20.18.

NVST has been the topic of a number of recent research reports. Piper Sandler lifted their price target on Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Morgan Stanley lowered their price objective on Envista from $20.00 to $19.00 and set an “equal weight” rating for the company in a research report on Thursday, March 6th. Mizuho assumed coverage on Envista in a research report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price objective for the company. Wells Fargo & Company set a $19.00 price objective on Envista in a research report on Saturday, March 8th. Finally, UBS Group lowered their price objective on Envista from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Monday, March 10th.

Envista Stock Performance

Shares of NVST stock opened at $17.16 on Friday. The business’s 50-day moving average price is $19.94 and its 200-day moving average price is $19.64. Envista has a 12 month low of $15.15 and a 12 month high of $23.00. The firm has a market capitalization of $2.95 billion, a price-to-earnings ratio of -2.64, a PEG ratio of 1.27 and a beta of 1.33. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Equities research analysts forecast that Envista will post 1 EPS for the current year.

Institutional Investors Weigh In On Envista

Several hedge funds and other institutional investors have recently modified their holdings of NVST. Huntington National Bank increased its holdings in shares of Envista by 97.8% during the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after acquiring an additional 949 shares in the last quarter. Venturi Wealth Management LLC increased its holdings in shares of Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after acquiring an additional 1,638 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Envista by 30.5% during the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after acquiring an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Envista during the fourth quarter valued at approximately $53,000. Finally, Mitsubishi UFJ Trust & Banking Corp purchased a new position in shares of Envista during the fourth quarter valued at approximately $86,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.